QM/MM and molecular dynamics investigation of the mechanism of covalent inhibition of TAK1 kinase
| dc.contributor.author | Borvornwat Toviwek | |
| dc.contributor.author | Duangkamol Gleeson | |
| dc.contributor.author | M. Paul Gleeson | |
| dc.date.accessioned | 2026-05-08T19:17:32Z | |
| dc.date.issued | 2021-1-1 | |
| dc.description.abstract | TAK1 is a serine/threonine kinase which is involved in the moderation of cell survival and death via the TNFα signalling pathway. It is also implicated in a range of cancer and anti-inflammatory diseases. Drug discovery efforts on this target have focused on both traditional reversible ATP-binding site inhibitors and increasingly popular irreversible covalent binding inhibitors. Irreversible inhibitors can offer benefits in terms of potency, selectivity and PK/PD meaning they are increasingly pursued where the strategy exists. TAK1 kinase differs from the better-known kinase EGFR in that the reactive cysteine nucleophile targeted by electrophilic inhibitors is located towards the back of the ATP binding site, not at its mouth. While a wealth of structural and computational effort has been spent exploring EGFR, only limited studies on TAK1 have been reported. In this work we report the first QM/MM study on TAK1 aiming to better understand aspects of covalent adduct formation. Our goal is to identify the general base in the catalytic reaction, whether the process proceeds via a stepwise or concerted pathway, and how the highly flexible G-loop and A-loop affect the catalytic cysteine located nearby. | |
| dc.identifier.doi | 10.1039/d0ob02273j | |
| dc.identifier.uri | https://dspace.kmitl.ac.th/handle/123456789/16087 | |
| dc.publisher | Organic & Biomolecular Chemistry | |
| dc.subject | Bioactive Compounds and Antitumor Agents | |
| dc.subject | Melanoma and MAPK Pathways | |
| dc.subject | Computational Drug Discovery Methods | |
| dc.title | QM/MM and molecular dynamics investigation of the mechanism of covalent inhibition of TAK1 kinase | |
| dc.type | Article |